clinical trial · NCT05190471
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryBP1002; Liposomal Bcl-2 Antisense OligodeoxynucleotideDecitabine (in combination with BP1002)
brief summary
This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).
started
Aug 16, 2022
primary completion
Mar 1, 2027
completion
Sep 1, 2027
last updated
Mar 10, 2025
official title
A Phase I/Ib Study of BP1002 (a Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol